A 48-year-old woman with stage IVB nasopharyngeal carcinoma (metastatic to lung and bone) is being considered for first-line palliative chemotherapy. She has normal renal function and good performance status (ECOG 0). Which drug regimen is the preferred first-line choice for metastatic NPC?

Explanation

## First-Line Palliative Chemotherapy for Metastatic Nasopharyngeal Carcinoma **Key Point:** Gemcitabine + cisplatin (GC) is the preferred first-line palliative chemotherapy regimen for metastatic nasopharyngeal carcinoma, offering superior response rates and tolerability compared to cisplatin + 5-FU. ### Comparison of First-Line Regimens for Metastatic NPC | Regimen | Response Rate | Median OS | Toxicity Profile | Notes | |---------|---------------|-----------|------------------|-------| | **Gemcitabine + Cisplatin** | 50–60% | 15–18 months | Moderate; good tolerability | **Preferred first-line** | | Cisplatin + 5-FU | 40–50% | 12–15 months | Higher GI/hematologic toxicity | Older standard | | Paclitaxel monotherapy | 20–30% | 8–10 months | Neuropathy, alopecia | Insufficient for metastatic disease | | 5-FU monotherapy | <20% | <8 months | Variable | Rarely used as monotherapy | **High-Yield:** Gemcitabine + cisplatin has largely replaced cisplatin + 5-FU as the standard first-line regimen for metastatic NPC because it offers better response rates (50–60% vs. 40–50%), improved median overall survival (15–18 months), and a more favorable toxicity profile with less nausea and mucositis. ### Dosing of Gemcitabine + Cisplatin - **Gemcitabine:** 1000 mg/m² IV on days 1 and 8 - **Cisplatin:** 80 mg/m² IV on day 1 - Repeat every 3 weeks for 4–6 cycles **Clinical Pearl:** In cisplatin-ineligible patients (renal impairment, hearing loss, neuropathy), gemcitabine + carboplatin is an acceptable alternative. Immunotherapy with PD-L1 inhibitors (e.g., pembrolizumab, nivolumab) is increasingly used in combination with chemotherapy or as maintenance therapy for metastatic NPC, especially in EBV-positive disease. **Warning:** Cisplatin-based regimens require baseline renal function assessment, audiometry, and monitoring for cumulative nephrotoxicity and ototoxicity. Adequate hydration and mesna are essential. ```mermaid flowchart TD A[Metastatic NPC<br/>Stage IVB]:::outcome --> B{Cisplatin<br/>eligible?}:::decision B -->|Yes| C[Gemcitabine + Cisplatin<br/>First-line]:::action B -->|No| D[Gemcitabine + Carboplatin<br/>or Immunotherapy]:::action C --> E[4-6 cycles<br/>every 3 weeks]:::action D --> F[Assess response<br/>at 8-12 weeks]:::action E --> F F --> G{Response?}:::decision G -->|CR/PR| H[Continue or<br/>Maintenance therapy]:::action G -->|SD/PD| I[Second-line regimen<br/>or Clinical trial]:::action ``` [cite:NCCN Guidelines Head and Neck Cancers 2023]